Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.

Christof M KazdaJuliana M Bue-ValleskeyJenny ChienQianyi ZhangEmmanuel ChigutsaWilliam LandschulzPaula WullenweberAxel HauptDominik Dahl

Published in: Diabetes care (2023)

Once-weekly BIF demonstrated noninferior glycemic control to once-daily degludec (treatment difference: 0.17% favoring degludec) and no difference in hypoglycemia or other safety findings in patients with T1D.

Keyphrases

glycemic control
type diabetes
blood glucose
weight loss
insulin resistance
physical activity
skeletal muscle
smoking cessation